Purpose: Prevalent gene fusions in prostate cancer involve androgen-regulated promoters (primarily TMPRSS2) and ETS transcription factors (predominantly ETS-regulated gene (ERG)], which result in tumor selective overexpression of ERG in two thirds of patients. Because diverse genomic fusion events lead to ERG overexpression in prostate cancer, we reasoned that it may be more practical to capture such alterations using an assay targeting ERG sequences retained in such gene fusions. This study evaluates the potential of an assay quantitating ERG mRNA in post-digital rectal exam (DRE) urine for improving prostate cancer detection.
The use of prostate-specific antigen (PSA) has revolutionized screening, management, and postintervention surveillance resulting in earlier diagnosis, downward stage migration, and expedited detection of recurrence after definitive therapy (1) . However, the excellent sensitivity of PSA is tempered by its poor specificity. There is an extensive research effort in progress to find an early detection modality without the limitations of PSA. Ideally, it would be one that complements PSA in such a way as to help identify patients who are likely to have disease that warrants definitive intervention.
Comparative evaluations of gene expression alterations in benign and malignant prostate epithelial cells from other groups and from our laboratory have defined frequent overexpression of PCA3, AMACR, and ETSregulated gene (ERG) in prostate tumor cells (2) (3) (4) (5) (6) . Our study further highlighted a combined specificity of >98% for PCA3, AMACR, and ERG in discriminating microdissected prostate tumor cells from normal prostatic epithelial cells (6) . The discovery of prevalent gene fusions involving regulatory sequences of the androgen receptor-regulated prostate-associated genes (predominantly TMPRSS2) and protein coding sequences of the nuclear transcription factors in the ETS gene family (ERG, ETV1, ETV4, ETV5, and ELK4; predominantly ERG) have defined the underlying genetic mechanism of frequent overexpression of the ERG family members in prostate tumors (5) (6) (7) (8) . Extensive evaluations of gene fusions involving ERG have highlighted exclusive prostate tumor cell association and the potential causal nature of ERG alterations in prostate cancer (8) .
Several investigators showed that useful diagnostic and even prognostic information can be obtained through the molecular genetic analysis of exfoliated prostatic epithelial cells found in the urine after digital rectal exam (DRE; refs. 2-4). Most of these studies evaluated the utility of PCA3 and/or TMPRSS2-ERG fusion assays (2, (4) (5) (6) (7) (8) (9) (10) (11) . Because diverse genomic fusion events may lead to ERG overexpression, we reasoned that it may be more practical to capture such alterations using assays targeting ERG sequences that are retained in all gene fusions involving ERG. In support of this hypothesis, our recent study confirmed higher frequency of overall ERG expression targeting ERG sequences 3′ to fusion compared with the detection of a common TMPRSS2-ERG fusion (12) . Our findings are also supported by a recent discovery of SLC45A3-ERG fusions in a subset of prostate cancer in addition to more frequent TMPRSS2-ERG fusions (13) . This study focuses on the diagnostic utility of quantitative measurements of ERG mRNA in post-DRE urine of prostate cancer patients.
Materials and Methods
Patient cohort and urine specimens. This study was approved by the Institutional Review Boards at Walter Reed Army Medical Center and the Uniformed Services University of Health Sciences. Patients were accrued between September 2006 and March 2008. Patients were excluded if they reported use of medications that would affect serum PSA levels (e.g., 5α-reductase inhibitors, herbal supplements, or the use of testosterone).
Urine samples were collected immediately following a DRE involving three sweeps of the physician's finger over both lateral lobes of the prostate. Samples were obtained immediately before prostate biopsy. ERG and PSA mRNA were measured using a DTS® 400 system, as previously described (2, 3, 8) . ERG mRNA was normalized to PSA mRNA in each sample. This score was then correlated to transrectal ultrasound-guided needle prostate biopsy result. A total of 12 cores were obtained from each patient. Three cores were taken from the base, middle, and apex of each lateral lobe with three additional biopsies taken from the more lateral base, middle, and apical regions. Urine samples were processed within 4 h of collection by mixing with an equal volume of detergent-based stabilization buffer (urine transport medium) to lyse cells and stabilize RNA. The urine transport medium was the same formulation that is found in the APTIMA® Urine Specimen Collection kit for Male and Female Urine Specimens (Gen-Probe Incorporated). Once processed, specimens were stored at −70C until they were tested.
All researchers collecting or processing specimens and collecting clinicopathologic data or doing ERG assays were blinded to results until a biostatistician provided the data.
Biomarker assay procedure. ERG and PSA mRNA levels were quantified using a urine assay. Target mRNA was captured onto magnetic microparticles coated with sequence-specific oligonucleotides. Transcription-mediated amplification of mRNA was followed by detection with chemiluminescent DNA probes. Transcript calibrators were then used to quantify ERG and PSA mRNA. The ERG score was calculated using the following equation:
The components for the ERG and PSA mRNA assays include analyte-specific (ERG and PSA) target capture, amplification, and probe reagents. The ERG target capture oligo sequence, primers, and probe targeted the 3′ untranslated region of ERG mRNA, the same region targeted previously in our quantitative reverse transcription-PCR assays (9) . The PSA target capture oligo sequence, primers, and probe targeted the exon 2/3 splice junction in the PSA mRNA. All other reagent formulations are identical to the corresponding Gen-Probe PROGENSA PCA3® reagents. The ERG and PSA assay protocols are identical and the reagent addition volumes and incubation times and temperatures specified in Gen-Probe PROGENSA PCA3® reagents.
Statistical analysis. Demographic and biopsy characteristics of the study sample were examined. Frequencies were reported for categorical patient features, whereas measures of central tendency (mean and median) and dispersion (SD and range) were reported for continuous patient features. The Wilcoxon rank-sum test or the Kruskal-Wallis test were used to examine the association between urine ERG score and patient demographic and biopsy features. Logistic regression and receiver operating characteristic (ROC) analysis were used to examine the biopsy prediction value of urine ERG score. A cutoff value of continuous ERG score was identified by using the minimum P value approach according to Mazumdar and Glassman (14) in multivariate extension. The cutoff value of continuous ERG score was identified by using minimum P value
Translational Relevance
The use of urine biomarkers to assist in diagnosing and prognosticating prostate cancer is a promising new strategy. Frequent overexpression of ETS-regulated gene (ERG), as a result of cancer-specific gene fusion events, represents the most common oncogenic activation in prostate cancer. This study highlights a new utility of ERG mRNA measurements in post-digital rectal exam urine especially in a defined patient cohort [prostate-specific antigen (PSA) ≤4.0 ng/mL] in which serum PSA test is least specific and, therefore, further diagnostic markers are needed to determine in whom biopsy should be done. The impressive performance of urine ERG score in predicting the biopsy result for this cohort of patients indicates that this assay has a potential translational relevance in determining which patients with minimally elevated serum PSA may undergo prostate biopsy. approach according to Mazumdar and Glassman (14) in multivariate extension. All observed values of ERG score, except a proportion of top and bottom 10% of the extreme values in the data (15), were examined as candidates for the cutpoint (C 1 ,C 2 ,C 3 ,…). To simplify the calculation, ERG score was rounded to integers. The i th cutpoint of ERG score is chosen using its association with biopsy outcome (biopsy) and it is known that other variables such as age, race, and serum PSA affect this relationship. Then, the χ 2 due to the i th cutpoint of ERG score was defined as:
in which the log likelihoods were obtained from corresponding multivariate logistic regression models. The value that best separates biopsy outcomes according to the maximum χ 2 statistic was chosen. A P value of 0.05 was adopted as statistically significant. The SAS version 9.1 was used for all data analysis.
Results
A total of 269 men provided urine before undergoing prostate biopsy. Measurement of urine ERG was not done in 32 men due to insufficient urine volume or due to PSA mRNA concentration of <7,500 c/mL. Prebiopsy characteristics of the 237 patients included in the final analysis is provided in Table 1 . Notably, the study group included 31.6% African-American men. Ninety-seven (40.9%) men showed adenocarcinoma of the prostate on biopsy. The majority of the patients were clinical stage T1 and had low-grade disease (Gleason score 5-6) on biopsy (Table 1) .
Higher urine ERG score associated significantly with a positive biopsy (P = 0.0145; Table 2 ). No significant association of urine ERG score with race or a family history, as defined as prostate cancer in a first-degree relative, was noted. Urine ERG score did not correlate with clinical stage or biopsy Gleason sum.
Using ROC analysis, an ERG score cutoff of 144 yielded a sensitivity of 31%, specificity of 84%, and AUC of 0.592. The number of positive cases for ERG in patients with positive and negative biopsies were 30 of 97 (30.9%) and 23 of 140 (16.4%), respectively. We evaluated the performance of the urine ERG score in relation to serum PSA cutoff of 4.0 ng/ mL, which is widely used in prostate cancer screening. ERG showed improved specificity, but decreased sensitivity when compared with serum PSA using a cutoff of 4.0 ng/mL. When evaluating all patients, adding urine ERG to serum PSA and other clinical parameters in a multivariate logistic regression model did not significantly improve performance in predicting positive biopsy (Table 3) .
Although there was no difference in urine ERG score predicted by race alone (Table 2) , urine ERG score performed better in predicting prostate cancer in Caucasians with an AUC of 0.678, as well as in patients with serum PSA ≤4 ng/mL with an AUC of 0.679 (Table 4) . No significant differences in clinical stage, biopsy Gleason score, or mean serum PSA was appreciated between African-Americans and Caucasians.
The most significant finding of this study was the predictive ability (AUC of 0.802) of ERG score in Caucasians with serum PSA ≤4 ng/mL (n = 62; Fig. 1 ). ERG score cutoff of 150 yielded a sensitivity of 50%, specificity of 95% and accuracy of 79% (Table 5 ). The AUC of ERG score among African-American s with serum PSA ≤4 ng/mL was 0.660 (data not shown).
Discussion
Frequent overexpression of ERG, as a result of cancerspecific gene fusion events, represents the most common oncogenic activation in prostate cancer. This study highlights the potential use of ERG mRNA measurements in post-DRE urine especially in a defined patient cohort (PSA, ≤4.0 ng/mL) in which serum PSA test is least specific.
Recent studies have evaluated the value of prostate cancer-associated gene expression detection in post-DRE urine. Laxman et al. (11) reported the detection of TMPRSS2-ERG fusion transcripts using qPCR in 8 of 19 (42%) patients who showed prostate cancer on biopsy. Hessels et al. (10) evaluated TMPRSS2-ERG fusion transcripts in post-DRE urine of 108 patients undergoing prostate biopsy, 78 of which showed prostate cancer. This study revealed 37% sensitivity and 93% specificity of TMPRSS2-ERG, and when combined with PCA3, sensitivity increased to 73%. Laxman et al. (9) investigated the use of a panel of seven markers: PCA3, ERG, AMACR, TMPRSS2-ERG fusion, SPINK1, TFF3, and GOLPH2. In this analysis, PCA3, GOLPH2, and TMPRSS2-ERG fusion showed a significant association with prostate cancer in either biopsy or prostatectomy specimens. In contrast to the present study, ERG expression was not significantly associated with prostate cancer on biopsy or prostatectomy. The investigators constructed a predictive model that included only those biomarkers that showed a significant association with malignancy on univariate analysis. This resulted in an improved AUC of 0.758.
Our study highlights a potential new utility of measuring ERG in post-DRE urine of a defined patient cohort. Despite a consensus that prostate cancer is being overdiagnosed due in large part to PSA screening, recent years have seen a move toward biopsying younger men for lower PSAs and decreased velocities than had been previously recommended. Thompson et al. (16) reported that 15.2% of patients with a PSA of <4.0 ng/mL and a normal DRE were diagnosed with prostate cancer. Of these patients, 14.9% showed a Gleason score of >7. Carter et al. (17) reported that in men with a pretreatment PSA of <4.0 ng/mL, a PSA velocity of >0.35 ng/mL/y was associated with a significantly worsened cancer-specific survival than those with a PSA velocity below this cutoff. Thus, PSA alone is not sufficient in determining which patients have more aggressive disease. The impressive performance of urine ERG score in predicting biopsy result for Caucasian patients with a PSA value of ≤4.0 ng/mL may indicate that this assay has a potential in determining which patients should undergo prostate biopsy in this subgroup. The reason for differences in the performance of ERG assays between Caucasian American and African-American patients are not clear at this stage, although we have previously noted the decreased ERG expression in prostate tumor cells of African-American patients (6). This observation warrants future investigations. Taken together, novel observation on diagnostic potential of ERG score in a defined patient cohort warrants further investigations as a urologist faced with a younger patient whose PSA is below 4.0 ng/mL and a marginal PSA velocity may be able to use a urine ERG score to determine whether the patient should be biopsied or observed.
Conclusion
The use of prostate cancer-specific biomarkers in urine to assist in diagnosing and prognosticating prostate cancer is a promising new strategy. This study shows the performance of urine ERG score that approximates serum PSA in predicting prostate biopsy results. Importantly, urine ERG score performed particularly well (AUC = 0.8) in Caucasian men with a PSA of ≤4.0 ng/mL, a segment of the screening population in which further diagnostic markers are needed to determine in whom biopsy should be done. Further studies examining the long-term prognostic significance of these markers will show their full potential in augmenting the appropriate diagnosis and treatment of prostate cancer. Recent studies have reported higher specificity and moderate sensitivity of urine PCA3 (3, 18) and TMPRSS2-ERG fusion assays (9) (10) (11) . The urine ERG assay described in this study may complement other urine biomarker assays in enhancing sensitivity for predicting positive biopsy in patients with minimally elevated serum PSA of ≤4 ng/mL. 
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